KKR will acquire Integer Holdings in an all-cash transaction valued at approximately $5.7 billion, taking the medical-device contract development and manufacturing organization private by year-end. The deal removes one of the largest publicly traded CDMOs from the market and marks KKR's third significant medical-device infrastructure play in twelve months.
Integer manufactures components and finished devices across cardiac rhythm management, neuromodulation, and vascular access. The company reported $1.6 billion in trailing revenue and operates 19 manufacturing sites in eight countries. Integer's customer base includes every major cardiovascular and neurostimulation device maker. KKR did not disclose the per-share price or premium to the recent trading range. The transaction is structured as a take-private with no disclosed financing contingencies.
This acquisition extends a clear pattern. Private equity has now announced $14.2 billion in medical-device CDMO acquisitions since January, with KKR, Carlyle, and Permira each taking public manufacturers off the board. The thesis is identical across deals: public markets undervalue contract-manufacturing businesses because analysts focus on end-device innovation rather than the oligopolistic infrastructure that makes those devices possible. Integer's customer contracts span multi-year supply agreements with embedded minimum-volume commitments. The business generates cash predictably. Public shareholders demanded growth multiples. Private equity pays for contracted cash flow and operates without quarterly calls.
The timing matters. Device makers are offloading capital-intensive manufacturing to focus on R&D and regulatory pathways. The FDA's recent shift toward pre-certification frameworks and modular approvals increases the value of vertically integrated manufacturing partners who can pivot production lines without full revalidation cycles. Integer's 19 sites give it geographic redundancy and dual-sourcing capacity that customers now require in supply-chain contracts. KKR inherits contracted revenue with structural switching costs. The company has no disclosed debt-refinancing pressure through 2027.
Operators should watch for two follow-on moves. First, whether KKR consolidates Integer with any of its existing medtech holdings, particularly in electrophysiology where component overlap is high. Second, how quickly the company accelerates capacity expansions in vascular-access manufacturing, where backlog has been building since mid-2023. Any acquisition of smaller single-site CDMOs by Integer within six months would signal KKR is building a roll-up platform rather than a standalone hold. The private-equity playbook here is not cost-cutting. It is revenue acceleration through customer lock-in and modular site expansion.
The deal is expected to close in Q4 2024. Integer's executive team remains in place. No site closures have been announced.